Amphastar P (AMPH)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 54.49% | 49.87% | 45.63% | 40.97% | 40.92% |
| Operating profit margin | 30.57% | 21.54% | 15.96% | 3.13% | -0.01% |
| Pretax margin | 26.28% | 23.02% | 18.90% | 1.41% | 19.44% |
| Net profit margin | 21.34% | 18.31% | 14.19% | 0.40% | 15.18% |
Amphastar Pharmaceuticals Inc has shown a positive trend in profitability ratios over the past five years. The gross profit margin has consistently improved, indicating better cost management and pricing strategies. The operating profit margin has experienced significant growth, reflecting improved operational efficiency and cost control measures. The pretax margin has also increased steadily, showing enhanced profitability before accounting for taxes. The net profit margin has shown a positive trajectory, reaching a peak in 2023, which indicates the company's ability to generate profit after all expenses, including taxes. Overall, the profitability ratios show that Amphastar Pharmaceuticals Inc has demonstrated consistent improvements in profitability over the past five years, which is a positive sign for investors and stakeholders.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 13.02% | 14.49% | 10.41% | 1.74% | -0.01% |
| Return on assets (ROA) | 9.09% | 12.32% | 9.25% | 0.22% | 8.34% |
| Return on total capital | 15.82% | 19.28% | 15.97% | 1.19% | 14.68% |
| Return on equity (ROE) | 21.51% | 17.29% | 13.94% | 0.35% | 12.83% |
Amphastar Pharmaceuticals Inc's profitability ratios show a varying trend over the past five years.
Operating return on assets (Operating ROA) has fluctuated, ranging from -0.01% in 2019 to a peak of 14.49% in 2022. This ratio measures the company's ability to generate operating income from its assets, with 2023 showing a moderate decrease compared to the previous year.
Return on assets (ROA) has also shown fluctuations, with a peak of 12.32% in 2022 and a low of 0.22% in 2020. ROA indicates how profitable a company is relative to its total assets, with a significant decrease in 2020 followed by a moderate upturn in the subsequent years.
Return on total capital has exhibited a similar trend, peaking at 17.59% in 2022 and hitting a low of 2.44% in 2020. This ratio reflects the efficiency of both equity and debt capital utilization by the company.
Return on equity (ROE) has shown a more consistent increase, starting at 12.83% in 2019 and reaching 21.51% in 2023. ROE illustrates how well the company generates profits from shareholders' equity, with 2023 demonstrating a notable improvement compared to previous years.
Overall, while there have been fluctuations in the profitability ratios of Amphastar Pharmaceuticals Inc over the past five years, there is a general trend of improvement in certain key ratios, indicating enhanced profitability and efficiency in utilizing assets and capital.